Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Peking Univ. Health Science Center PRMT5 compound 43g
- Development stage
- Unknown
- Lead developer
- Peking University Health Science Center
01
Overview
Peking Univ. Health Science Center PRMT5 compound 43g: sourced facts only. name: "Moreover, 43g selectively inhibited PRMT5 among protein arginine methyltransferase isoforms." [PMID:35748226]; target: "Moreover, 43g selectively inhibited PRMT5 among protein arginine methyltransferase isoforms." [PMID:35748226]; developer: "Department of Pathology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China." [PMID:35748226]
02
Targets
PRMT5 (Protein arginine N-methyltransferase 5)
Beyond the preview
Go deeper on Peking Univ. Health Science Center PRMT5 compound 43g.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peking Univ. Health Science Center PRMT5 compound 43g.